Head-flat positioning before thrombectomy linked to better outcomes

Data suggest maintaining 0° head position pre-EVT improves stability and outcomes in LVO stroke candidates.

ACC/AHA publish 2025 hypertension guideline (stroke-relevant)

New guideline emphasizes prevention, earlier treatment when needed, and individualized risk assessment.

Donanemab receives CHMP positive opinion for early Alzheimer’s

CHMP backs donanemab for early symptomatic AD; EC decision next for EU availability.

FDA issues CRL for vatiquinone in Friedreich’s ataxia

Agency requests an additional adequate, well-controlled study before resubmission.

Efgartigimod hits endpoint in seronegative gMG (ADAPT SERON)

Phase 3 topline shows clinically meaningful benefit across MuSK+, LRP4+, and triple-seronegative subgroups.

CHMP positive opinion for Aqneursa (levacetylleucine) in NPC

Supports treatment of neurological manifestations in adults and children ≥6 years.

FDA approves Genio hypoglossal nerve stimulator for OSA

PMA approval confirms neurostimulation option for moderate–severe OSA (AHI 15–65).

FDA authorizes AI brain-mapping software for neurosurgery/epilepsy

Machine-learning platform enhances anatomical localization and mapping to guide resections and invasive monitoring.

CHMP recommends EU approval; targeted option to delay radiochemotherapy

Therapeutic options: Post-resection IDH-mutant grade 2 glioma care has been a balance between active surveillance and early radiochemotherapy (RT/TMZ) with long-term cognitive and systemic toxicity risks. A brain-penetrant, oral IDH1/2 inhibitor introduces a third path: targeted disease control while delaying RT/TMZ exposure. 🔄

Trial population & design: Phase 3 INDIGO enrolled adults with residual/non-enhancing IDH-mutant grade 2 glioma after surgery, randomized to vorasidenib vs placebo; primary endpoint PFS, key secondary endpoint time-to-next-intervention.

Efficacy: Median PFS 27.7 vs 11.1 months (HR 0.39); time-to-next-intervention HR 0.26 — demonstrating durable disease control and postponement of RT/TMZ.

Safety/monitoring: Grade ≥3 AEs 22.8% vs 13.5% (ALT/AST elevations most common); no treatment-related deaths. Practical points: baseline and periodic LFTs, MRI surveillance, dose holds/reductions as needed.

Clinical takeaway: Pending EC ratification, vorasidenib would be the first targeted oral therapy for this setting, enabling a “preserve cognition, delay toxicity” strategy within multidisciplinary neuro-oncology pathways. ✅